Skip to main content

Advertisement

SpringerLink
Log in

Immune Monitoring of Islet and Pancreas Transplant Recipients

  • Transplantation (A Pileggi, Section Editor)
  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Type 1 diabetes (T1D) is an autoimmune disease in which the insulin-producing beta-cells are destroyed. Islet or pancreas transplantation can restore insulin secretion and are established therapies for subgroups of T1D patients. Long-term insulin-independence is, however, hampered by recurrent autoimmunity and rejection. Accurate monitoring of these immune events is therefore of critical relevance for the timely detection of deleterious immune responses. The identification of relevant immune biomarkers of allo- and autoreactivity has allowed a more accurate monitoring of disease progression and responses to therapy at early stages, allowing proper therapeutic intervention, and possibly improvements in the success rate of islet and pancreas transplantation. This review describes the tools established and validated to monitor immune correlates of auto- and alloreactivity that associate with clinical outcome and identifies challenges that current immunosuppression strategies trying to preserve islet graft function face.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. • Coppieters KT, Dotta F, Amirian N, Campbell PD, Kay TW, Atkinson MA, et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med. 2012;209:51–60. Ultimate proof that insulitis in human pancreatic leasions contain islet auoreactive CD8 T cells.

    Article  PubMed  CAS  Google Scholar 

  2. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care. 2003;26:832–6.

    Article  PubMed  Google Scholar 

  3. Barton FB, Rickels MR, Alejandro R, Hering BJ, Wease S, Naziruddin B, et al. Improvement in outcomes of clinical islet transplantation: 1999–2010. Diabetes Care. 2012;35:1436–45.

    Article  PubMed  CAS  Google Scholar 

  4. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, et al. Five-year follow-up after clinical islet transplantation. Diabetes. 2005;54:2060–9.

    Article  PubMed  CAS  Google Scholar 

  5. Shapiro AM. State of the art of clinical islet transplantation and novel protocols of immunosuppression. Curr Diab Rep. 2011;11:345–54.

    Article  PubMed  Google Scholar 

  6. Ziegler AG, Nepom GT. Prediction and pathogenesis in type 1 diabetes. Immunity. 2010;32:468–78.

    Article  PubMed  CAS  Google Scholar 

  7. Martin S, Wolf-Eichbaum D, Duinkerken G, Scherbaum WA, Kolb H, Noordzij JG, et al. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med. 2001;345:1036–40.

    Article  PubMed  CAS  Google Scholar 

  8. Bosi E, Bottazzo GF, Secchi A, Pozza G, Shattock M, Saunders A, et al. Islet cell autoimmunity in type I diabetic patients after HLA-mismatched pancreas transplantation. Diabetes. 1989;38 Suppl 1:82–4.

    PubMed  Google Scholar 

  9. Braghi S, Bonifacio E, Secchi A, Di CV, Pozza G, Bosi E. Modulation of humoral islet autoimmunity by pancreas allotransplantation influences allograft outcome in patients with type 1 diabetes. Diabetes. 2000;49:218–24.

    Article  PubMed  CAS  Google Scholar 

  10. • Vendrame F, Pileggi A, Laughlin E, Allende G, Martin-Pagola A, Molano RD, et al. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes. 2010;59:947–57. First evidence that recuurent autoimmunity may be cause of chronic loss of function in pancreas allograft recipients.

    Article  PubMed  CAS  Google Scholar 

  11. Jaeger C, Brendel MD, Hering BJ, Eckhard M, Bretzel RG. Progressive islet graft failure occurs significantly earlier in autoantibody-positive than in autoantibody-negative IDDM recipients of intrahepatic islet allografts. Diabetes. 1997;46:1907–10.

    Article  PubMed  CAS  Google Scholar 

  12. Piemonti L, Everly MJ, Maffi P, Scavini M, Poli F, Nano R, et al. Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 Diabetes. Diabetes. 2012;62:1656–64.

    Google Scholar 

  13. Hilbrands R, Huurman VA, Gillard P, Velthuis JH, De WM, Mathieu C, et al. Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients. Diabetes. 2009;58:2267–76.

    Article  PubMed  CAS  Google Scholar 

  14. • Huurman VA, Hilbrands R, Pinkse GG, Gillard P, Duinkerken G, van de Linde P, et al. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS One. 2008;3:e2435. First evidence that cellular islet autoimmunity before transplantation determines outcome, rather than islet autoantibodies at baseline. Alloreactivity to the islet donor proved secondary to recurrent islet autoimmunity.

    Article  PubMed  Google Scholar 

  15. Huurman VA, van der Torren CR, Gillard P, Hilbrands R, van der Meer-Prins EP, Duinkerken G, et al. Immune responses against islet allografts during tapering of immunosuppression–a pilot study in 5 subjects. Clin Exp Immunol. 2012;169:190–8.

    Article  PubMed  CAS  Google Scholar 

  16. Laughlin E, Burke G, Pugliese A, Falk B, Nepom G. Recurrence of autoreactive antigen-specific CD4+ T cells in autoimmune diabetes after pancreas transplantation. Clin Immunol. 2008;128:23–30.

    Article  PubMed  CAS  Google Scholar 

  17. • Monti P, Scirpoli M, Maffi P, Ghidoli N, de Taddeo F, Bertuzzi F, et al. Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. J Clin Invest. 2008;118:1806–14. Demonstration of homeostatic expansion by islet auoreactive memory CD8 T cells following debulking induction therapy with thymoglobulin before islet transplantation.

    PubMed  CAS  Google Scholar 

  18. Pinkse GG, Tysma OH, Bergen CA, Kester MG, Ossendorp F, van Veelen PA, et al. Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc Natl Acad Sci USA. 2005;102:18425–30.

    Article  PubMed  CAS  Google Scholar 

  19. Roep BO, Stobbe I, Duinkerken G, van Rood JJ, Lernmark A, Keymeulen B, et al. Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. Diabetes. 1999;48:484–90.

    Article  PubMed  CAS  Google Scholar 

  20. Unger WW, Velthuis J, Abreu JR, Laban S, Quinten E, Kester MG, et al. Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers. J Autoimmun. 2011;37:151–9.

    Article  PubMed  CAS  Google Scholar 

  21. Velthuis JH, Unger WW, van der Slik AR, Duinkerken G, Engelse M, Schaapherder AF, et al. Accumulation of autoreactive effector T cells and allo-specific regulatory T cells in the pancreas allograft of a type 1 diabetic recipient. Diabetologia. 2009;52:494–503.

    Article  PubMed  CAS  Google Scholar 

  22. Velthuis JH, Unger WW, Abreu JR, Duinkerken G, Franken K, Peakman M, et al. Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. Diabetes. 2010;59:1721–30.

    Article  PubMed  CAS  Google Scholar 

  23. Trudeau JD, Kelly-Smith C, Verchere CB, Elliott JF, Dutz JP, Finegood DT, et al. Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. J Clin Invest. 2003;111:217–23.

    PubMed  CAS  Google Scholar 

  24. Unger WW, Pearson T, Abreu JR, Laban S, van der Slik AR, der Kracht SM, et al. Islet-specific CTL cloned from a type 1 diabetes patient cause beta-cell destruction after engraftment into HLA-A2 transgenic NOD/scid/IL2RG null mice. PLoS One. 2012;7:e49213.

    Article  PubMed  CAS  Google Scholar 

  25. Abreu JR, Roep BO. Autoreactive CD8 T cells in Type 1 diabetes: implications for pathogenesis, diagnosis, disease progression, and therapeutic intervention. Diabetes Management. 2011;1:99–108.

    Article  CAS  Google Scholar 

  26. Campbell PM, Salam A, Ryan EA, Senior P, Paty BW, Bigam D, et al. Pretransplant HLA antibodies are associated with reduced graft survival after clinical islet transplantation. Am J Transplant. 2007;7:1242–8.

    Article  PubMed  CAS  Google Scholar 

  27. Mohanakumar T, Narayanan K, Desai N, Ramachandran S, Shenoy S, Jendrisak M, et al. A significant role for histocompatibility in human islet transplantation. Transplantation. 2006;82:180–7.

    Article  PubMed  CAS  Google Scholar 

  28. Olack BJ, Swanson CJ, Flavin KS, Phelan D, Brennan DC, White NH, et al. Sensitization to HLA antigens in islet recipients with failing transplants. Transplant Proc. 1997;29:2268–9.

    Article  PubMed  CAS  Google Scholar 

  29. Cardani R, Pileggi A, Ricordi C, Gomez C, Baidal DA, Ponte GG, et al. Allosensitization of islet allograft recipients. Transplantation. 2007;84:1413–27.

    Article  PubMed  Google Scholar 

  30. Kessler L, Parissiadis A, Bayle F, Moreau F, Pinget M, Froelich N, et al. Evidence for humoral rejection of a pancreatic islet graft and rescue with rituximab and IV immunoglobulin therapy. Am J Transplant. 2009;9:1961–6.

    Article  PubMed  CAS  Google Scholar 

  31. Lobo PI, Spencer C, Simmons WD, Hagspiel KD, Angle JF, Deng S, et al. Development of anti-human leukocyte antigen class 1 antibodies following allogeneic islet cell transplantation. Transplant Proc. 2005;37:3438–40.

    Article  PubMed  CAS  Google Scholar 

  32. • Campbell PM, Senior PA, Salam A, Labranche K, Bigam DL, Kneteman NM, et al. High risk of sensitization after failed islet transplantation. Am J Transplant. 2007;7:2311–7. Demonstration of immunization to donor HLA after islet transplantation.

    Article  PubMed  CAS  Google Scholar 

  33. Roelen DL, Huurman VA, Hilbrands R, Gillard P, Duinkerken G, van der Meer-Prins PW, et al. Relevance of cytotoxic alloreactivity under different immunosuppressive regimens in clinical islet cell transplantation. Clin Exp Immunol. 2009;156:141–8.

    Article  PubMed  CAS  Google Scholar 

  34. Stobbe I, Duinkerken G, van Rood JJ, Lernmark A, Keymeulen B, Pipeleers D, et al. Tolerance to kidney allograft transplanted into Type I diabetic patients persists after in vivo challenge with pancreatic islet allografts that express repeated mismatches. Diabetologia. 1999;42:1379–80.

    Article  PubMed  CAS  Google Scholar 

  35. van Kampen CA, van de Linde P, Duinkerken G, van Schip JJ, Roelen DL, Keymeulen B, et al. Alloreactivity against repeated HLA mismatches of sequential islet grafts transplanted in non-uremic type 1 diabetes patients. Transplantation. 2005;80:118–26.

    Article  PubMed  Google Scholar 

  36. Huurman VA, Velthuis JH, Hilbrands R, Tree TI, Gillard P, van der Meer-Prins PM, et al. Allograft-specific cytokine profiles associate with clinical outcome after islet cell transplantation. Am J Transplant. 2009;9:382–8.

    Article  PubMed  CAS  Google Scholar 

  37. Sibley RK, Sutherland DE, Goetz F, Michael AF. Recurrent diabetes mellitus in the pancreas iso- and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. Lab Invest. 1985;53:132–44.

    PubMed  CAS  Google Scholar 

  38. Sibley RK, Sutherland DE. Pancreas transplantation. An immunohistologic and histopathologic examination of 100 grafts. Am J Pathol. 1987;128:151–70.

    PubMed  CAS  Google Scholar 

  39. Sutherland DE, Sibley R, Xu XZ, Michael A, Srikanta AM, Taub F, et al. Twin-to-twin pancreas transplantation: reversal and reenactment of the pathogenesis of type I diabetes. Trans Assoc Am Physicians. 1984;97:80–7.

    PubMed  CAS  Google Scholar 

  40. Sutherland DE, Goetz FC, Sibley RK. Recurrence of disease in pancreas transplants. Diabetes. 1989;38 Suppl 1:85–7.

    PubMed  Google Scholar 

  41. Monti P, Scirpoli M, Rigamonti A, Mayr A, Jaeger A, Bonfanti R, et al. Evidence for in vivo primed and expanded autoreactive T cells as a specific feature of patients with type 1 diabetes. J Immunol. 2007;179:5785–92.

    PubMed  CAS  Google Scholar 

  42. Danke NA, Yang J, Greenbaum C, Kwok WW. Comparative study of GAD65-specific CD4+ T cells in healthy and type 1 diabetic subjects. J Autoimmun. 2005;25:303–11.

    Article  PubMed  CAS  Google Scholar 

  43. Viglietta V, Kent SC, Orban T, Hafler DA. GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes. J Clin Invest. 2002;109:895–903.

    PubMed  CAS  Google Scholar 

  44. Alkemade GM, Clemente-Casares X, Yu Z, Xu BY, Wang J, Tsai S, et al. Local autoantigen expression as essential gatekeeper of memory T-cell recruitment to islet grafts in diabetic hosts. Diabetes. 2012;[In press].

  45. Gillard P, Huurman V, Van der Auwera B, Decallonne B, Poppe K, Roep BO, et al. Graves hyperthyroidism after stopping immunosuppressive therapy in type 1 diabetic Islet cell recipients with pretransplant TPO autoantibodies. Diabetes Care. 2009;32:1817–9.

    Article  PubMed  CAS  Google Scholar 

  46. Keymeulen B, Gillard P, Mathieu C, Movahedi B, Maleux G, Delvaux G, et al. Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft. Proc Natl Acad Sci USA. 2006;103:17444–9.

    Article  PubMed  CAS  Google Scholar 

  47. Roep BO, Kleijwegt FS, van Halteren AG, Bonato V, Boggi U, Vendrame F, et al. Islet inflammation and CXCL10 in recent-onset type 1 diabetes. Clin Exp Immunol. 2010;159:338–43.

    Article  PubMed  CAS  Google Scholar 

  48. Valujskikh A, Li XC. Frontiers in nephrology: T cell memory as a barrier to transplant tolerance. J Am Soc Nephrol. 2007;18:2252–61.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors were supported by grants from the Juvenile Diabetes Research Foundation, the Dutch Diabetes Research Foundation, ZonMW (VICI award) and the European Union FP7 Program (BetaCellTherapy and NAIMT).

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

Joana R. F. Abreu declares that she has no conflict of interest.

Bart O. Roep has board membership with Diamyd, Andromeda; has been a consultant for Novo Nordisk, GlaxoSmithKline.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, E3-Q, P.O. Box 9600, NL-2300Rc, Leiden, The Netherlands

    J. R. F. Abreu & B. O. Roep

  2. JDRF Center for Beta Cell Therapy in Diabetes, Brussels, Belgium

    B. O. Roep

Authors
  1. J. R. F. Abreu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. O. Roep
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. O. Roep.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abreu, J.R.F., Roep, B.O. Immune Monitoring of Islet and Pancreas Transplant Recipients. Curr Diab Rep 13, 704–712 (2013). https://doi.org/10.1007/s11892-013-0399-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-013-0399-3

Keywords

Search

Navigation